Clinical Trials Browser

Neoplasm, Residual × Gastrointestinal × 90 days × Clear all

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Unknown Primary, Urogenital Neoplasms, Neoplasm, Residual

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

20 enrolled

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

100 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

Clinical Trials

SHERLOCK

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

TRACE-BTC

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial